Generated by AI
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types. The company’s current clinical programs center on difficult-to-treat solid tumors and hematologic malignancies, including colorectal cancer, prostate cancer, pancreatic cancer, lung cancer, and breast cancer. Cardiff Oncology’s work is aimed at addressing treatment resistance and improving the effectiveness of existing cancer regimens through combination approaches. Headquartered in San Diego, California, Cardiff Oncology operates as a focused oncology drug development company within the broader biotechnology sector.
Website11055 Flintkote Avenue
San Diego, CA, 92121
United States
The latest articles about CRDF.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about CRDF also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.